The Home Office have released their annual statistics on animals used in research in Great Britain. It shows 3.52 million procedures were carried out in 2018, a 7% decrease on the 2017 numbers.
A written ministerial statement from the Cabinet Office has been published this afternoon, along with a letter giving an update on the Government’s 'no deal' planning and guidance.
The Office for Life Sciences has today published its annual Life Science Competitiveness Indicators, which highlight the importance of the Industry to the UK economy.
Outgoing Chief Medical Officer Professor Dame Sally Davies has been named as UK Special Envoy on antimicrobial resistance (AMR), working across all sectors including includes health, agriculture and the environment to tackle the global health threat.
The ABPI has published a new guide for pharmaceutical companies working with patients.
The ABPI welcomes the news of the Government’s decision to reject three significant recommendations made by the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP) group following consultation with charities, patient groups, health bodies and organisations, and...
There has been much discussion in recent days on medicines pricing in the UK. The UK has some of the most robust processes in the world for ensuring value for money on medicines.
Today, 4 June, sees the unveiling of the UK’s newest life sciences asset, Health Innovation Research Alliance Northern Ireland (HIRANI) at a BIO reception in Philadelphia.
In light of the Government's announcement of an extension to article 50, ABPI commented on the position regarding stockpiling of medicines in preparation for a 'no-deal'.
Haseeb Ahmad, Managing Director, UK, Ireland & Nordics Novartis Pharmaceuticals and Country President Novartis UK has been confirmed as the new President of the ABPI.
The Government will today announce at the ABPI Conference that the most promising treatments will be fast-tracked by the new and boosted Accelerated Access Collaborative. Medicines, technologies and diagnostic tools targeting key health problems will be prioritised. The ABPI welcomes the move.